Classic chordoma coexisting with benign notochordal cell rest demonstrating different immunohistological expression patterns of brachyury and galectin-3
- PMID: 20855213
- DOI: 10.1016/j.jocn.2010.03.066
Classic chordoma coexisting with benign notochordal cell rest demonstrating different immunohistological expression patterns of brachyury and galectin-3
Abstract
Increasing numbers of studies support the hypothesis that chordoma arises from notochordal cell rests, although the mechanism awaits further research. Brachyury is the first specific molecule linking chordoma with the notochord, and galectin-3 has been widely used as a marker of notochordal cells. We conducted a histological study of the expression of these two molecules in 46 classic chordoma specimens and unexpectedly found that classic chordoma tumor cells coexisted with benign notochordal cell rests in six specimens. Brachyury and galectin-3 expression were investigated by immunohistochemistry. All specimens contained atypical chordoma tumor cells set within an abundant myxoid matrix, which strongly expressed brachyury and galectin-3. However, brachyury and galectin-3 were not expressed in the notochordal cells. Benign notochordal cells, present as notochord rests, could undergo malignant transformation to form chordoma; however, the cause and role of brachyury and galectin-3 expression in chordoma tumorigenesis requires further careful study.
2010 Elsevier Ltd. All rights reserved.
Similar articles
-
Histological study of chordoma origin from fetal notochordal cell rests.Spine (Phila Pa 1976). 2013 Dec 1;38(25):2165-70. doi: 10.1097/BRS.0000000000000010. Spine (Phila Pa 1976). 2013. PMID: 24296480
-
First histologically confirmed case of a classic chordoma arising in a precursor benign notochordal lesion: differential diagnosis of benign and malignant notochordal lesions.Skeletal Radiol. 2002 Jul;31(7):413-8. doi: 10.1007/s00256-002-0514-z. Epub 2002 May 15. Skeletal Radiol. 2002. PMID: 12107574 Review.
-
Revisiting chordoma with brachyury, a "new age" marker: analysis of a validation study on 51 cases.Arch Pathol Lab Med. 2010 Aug;134(8):1181-7. doi: 10.5858/2009-0476-OA.1. Arch Pathol Lab Med. 2010. PMID: 20670140
-
Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas.J Pathol. 2006 Jun;209(2):157-65. doi: 10.1002/path.1969. J Pathol. 2006. PMID: 16538613
-
Notochordal Tumors: An Update on Molecular Pathology with Therapeutic Implications.Surg Pathol Clin. 2017 Sep;10(3):637-656. doi: 10.1016/j.path.2017.04.008. Epub 2017 Jun 29. Surg Pathol Clin. 2017. PMID: 28797506 Review.
Cited by
-
The Clinical Outcomes of Cervical Spine Chordoma: A Nationwide Multicenter Retrospective Study.Neurospine. 2024 Sep;21(3):942-953. doi: 10.14245/ns.2448448.224. Epub 2024 Sep 30. Neurospine. 2024. PMID: 39363489 Free PMC article.
-
Benign notochordal cell tumor: a retrospective study of 11 cases with 13 vertebra bodies.Int J Clin Exp Pathol. 2014 Jun 15;7(7):3548-54. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25120733 Free PMC article.
-
Skull base chordomas review of current treatment paradigms.World J Otorhinolaryngol Head Neck Surg. 2020 Apr 18;6(2):125-131. doi: 10.1016/j.wjorl.2020.01.008. eCollection 2020 Jun. World J Otorhinolaryngol Head Neck Surg. 2020. PMID: 32596658 Free PMC article. Review.
-
The Roles of Embryonic Transcription Factor BRACHYURY in Tumorigenesis and Progression.Front Oncol. 2020 Jun 30;10:961. doi: 10.3389/fonc.2020.00961. eCollection 2020. Front Oncol. 2020. PMID: 32695672 Free PMC article. Review.
-
Difficulty distinguishing benign notochordal cell tumor from chordoma further suggests a link between them.Cancer Imaging. 2014 Apr 22;14(1):4. doi: 10.1186/1470-7330-14-4. Cancer Imaging. 2014. PMID: 25609192 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources